M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Celecoxib
Drug: Gemcitabine Hydrochloride

First Posted Date: 2003-09-11

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00068432

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

and more 8 locations

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2003-08-28

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT00067808

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pegfilgrastim (Neulasta)
Procedure: Apheresis

First Posted Date: 2003-08-26

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00067639

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myeloid Leukemia

Interventions: Drug: Ara-C 0.75 g/m^2
Drug: Idarubicin 10mg/m^2
Drug: Clofarabine 40mg/m^2
Drug: Ara-C 1 g/m^2
Drug: Clofarabine 22.5mg/m^2
Drug: Idarubicin 6 mg/m^2

First Posted Date: 2003-08-13

Last Posted Date: 2020-12-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00067028

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Randomized Double Cord Blood Transplant Study

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myelocytic, Acute
Leukemia, Myeloid, Chronic
Lymphoma, Non-Hodgkin

Interventions: Procedure: Expanded allogeneic cord blood (CB)
Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Drug: Rituxan
Drug: Melphalan
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Total body irradiation (TBI)

First Posted Date: 2003-08-11

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT00067002

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Bryostatin-1
Drug: Paclitaxel (Taxol)

First Posted Date: 2003-07-25

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00006081

Locations: 🇺🇸
CCOP - M.D. Anderson Research Base, Houston, Texas, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia, Myeloid
Myelodysplastic Syndromes

First Posted Date: 2003-07-18

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00065143

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Flutamide
Drug: Leuprolide Acetate

First Posted Date: 2003-07-15

Last Posted Date: 2020-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00003645

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: Recombinant Interferon Alfa (INF alpha)

First Posted Date: 2003-07-11

Last Posted Date: 2023-12-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00002965

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Tarceva (OSI-774)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2003-06-25

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00063258

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy